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Tumor cells resist the apoptotic stimuli associated with invasion and metastasis by activating survival
signals that suppress apoptosis. Focal adhesion kinase (FAK), a tyrosine kinase that is overexpressed in a
variety of human tumors, mediates one of these survival signals. Attenuation of FAK expression in tumor cells
results in apoptosis that is mediated by caspase 8- and FADD-dependent pathways, suggesting that death
receptor pathways are involved in the process. Here, we report a functional link between FAK and death
receptors. We have demonstrated that FAK binds to the death domain kinase receptor-interacting protein
(RIP). RIP is a major component of the death receptor complex and has been shown to interact with Fas and
tumor necrosis factor receptor 1 through its binding to adapter proteins. We have shown that RIP provides
proapoptotic signals that are suppressed by its binding to FAK. We thus propose that FAK overexpression in
human tumors provides a survival signal function by binding to RIP and inhibiting its interaction with the
death receptor complex.
Focal adhesion kinase (FAK) is a nonreceptor protein ty-
rosine kinase that plays a key role in maintaining focal adhe-
sion function and cell survival and is implicated in cell migra-
tion, adhesion, and cell cycle control (9, 13, 18, 20, 33, 44).
Overexpression of FAK is a common event in numerous tumor
systems, including breast, colon, and thyroid carcinomas (2, 24,
32, 41), and occurs at early stages of tumorigenesis, before a
tumor has developed the capacity for invasion and metastasis
(2). Importantly, FAK has been shown to be one of the critical
factors protecting cells from apoptosis, but the exact mecha-
nism is unknown (8, 9, 12, 19, 37, 43). Attenuation of FAK
expression by antisense oligonucleotides led to apoptosis in
tumor cells (42), and the treatment of cells with anti-FAK
antibody (18, 26) or overexpression of the focal adhesion tar-
geting (FAT) domain of FAK led to cell rounding, detach-
ment, and apoptosis (19, 21, 40). We have created a model
system for the attenuation of FAK function by adenoviral gene
transduction of the carboxy-terminal domain of FAK (FAK-
CD) and have demonstrated a loss of adhesion and apoptosis
in breast cancer cells with this treatment (43). Both anchorage-
dependent and anchorage-independent apoptotic signaling re-
quired Fas-associated death domain protein (FADD) and
caspase 8, suggesting an important role for FAK in inhibiting
death receptor-related apoptosis (43). This finding provided
additional evidence that a death receptor-mediated apoptotic
pathway or death receptor-related death domain proteins are
involved in the apoptotic process triggered by the expression of
FAK-CD.
The loss of adhesion and induction of apoptosis upon atten-
uation of FAK function by the expression of FAK-CD is sim-
ilar to the phenomenon of anoikis (7–9). Intriguingly, there is
evidence for the involvement of death receptor-related, death
domain-containing proteins in anoikis (7, 35), whereby the
silencer of death domain (SODD) and dominant-negative
FADD efficiently inhibited anoikis in Madin-Darby canine kid-
ney (MDCK) cells and in a number of untransformed epithe-
lial cell lines. In these studies, it was also shown that cell matrix
detachment activated caspase 8. However, the linkage of the
signaling pathways to the death receptors remains unknown.
RIP is a serine/threonine kinase that contains a death do-
main (17, 38) and is named for its association with the death
receptor complex. RIP interacts with the death domains of cell
surface receptors of the tumor necrosis factor (TNF) super-
family and death domain adaptor proteins (3, 5, 17) and plays
an indispensable role in NF-B activation (23, 39). Recently, it
was shown that TNF alpha-mediated activation of NF-B de-
pends on the association of RIP and FAK (11). TNF-induced
NF-B DNA binding activity and activation of IB kinases
were markedly impaired in FAK/ cells (11). However, it has
been well established that RIP has a dual function and is
capable of either inducing apoptosis or activating cellular sur-
vival signals (14, 17, 23, 27, 38, 39). Similarly, it has been
proposed that RIP is one of the switches between cell survival
and apoptosis (28). However, the mechanisms by which such
diverse functions are selected remain unclear.
To elucidate the possible protein(s) involved in apoptosis
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FIG. 1. Association between FAK and RIP in vivo and in vitro. (A) Human breast carcinoma cell line BT-474 was grown in monolayer. Binding
was analyzed by immunoprecipitation with anti-RIP antibody and then followed by immunoblotting with anti-FAK antibody or by immunopre-
cipitation with anti-FAK antibody against N terminus 4.47 or C terminus C20 followed by IB with anti-RIP antibody. Probe without antibody was
added as a control for background binding. (B) Tet-FAK cell lysates were immunoprecipitated with anti-FAK antibody followed by immunoblot-
ting with anti-RIP antibody. A Western blot of Tet-FAK cell lysates with RIP antibody was performed to evaluate RIP synthesis in the cells during
the time course of tetracycline withdrawal. Probe without antibody was added as a control for background binding. (C) HEK293 cells were
transiently cotransfected with pXpress-RIP along with pcDNA3, pcDNA3-FAK, pGFP C1 vector, pGFP-FAK-CD, or pGFP-FAK-NT. pCMV-
CrmA was also included in the transfections to protect the cells from apoptosis induced by the overexpression of RIP. After 24 h, cell lysates were
subjected to immunoprecipitation with anti-Xpress antibody. The immunopellets were analyzed by immunoblotting and probing with anti-FAK
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caused by the disruption of FAK signaling by expression of the
C-terminal domain of FAK, we tested several death domain
proteins for the ability to bind to FAK. We found that RIP
bound to FAK in vitro and in vivo in different mammalian cell
lines (normal and transformed), and the level of apoptosis
caused by the attenuation of FAK correlated with the level of
RIP expression in the particular cell line. In this report, we
show a possible mechanism by which the death receptor ma-
chinery is involved in anoikis through the interaction of FAK
and RIP.
MATERIALS AND METHODS
Cell culture. BT-474 and BT-20 human breast carcinoma cell lines were
cultured as described previously (43). Tet-FAK cells, whereby the tetracycline
repression system was implemented in FAK-null mouse embryonic fibroblasts to
modulate FAK expression, were cultured as described previously (31). RIP/
TNFR1/ and RIP/ TNFR1/ mouse embryonic fibroblasts (4) were kindly
provided by P. Leder and M. Kelliher (Harvard Medical School, Boston, Mass.).
HEK293 human embryonic kidney cells were cultured in Dulbecco modified
Eagle medium containing 10% fetal bovine serum. All cell lines were incubated
at 37°C in 5% CO2.
Plasmids, reagents, and antibodies. The mammalian expression vector encod-
ing hemagglutinin (HA)-FAK has been described previously (43). pXpress-RIP
and pMyc-RIP death domain were kindly provided by Zheng-gang Liu (National
Cancer Institute, National Institutes of Health, Bethesda, Md.). The glutathione
transferase (GST)-RIP construct was prepared by subcloning RIP into the SmaI
site of the pGEX-3X vector. The FAT sequence (nucleotides 2987 to 3391 of
FAK) was subcloned by PCR into the pGEX-4T-1 vector. GST-FAK-N terminus
(NT), green fluorescent protein (GFP)–FAK-NT, and GFP-FAK-CD were pre-
viously described (1). Staurosporine (Calbiochem) was used in 200 and 500 nM
concentrations. We used anti-FAK 4.47 (Upstate Biotechnology, Inc.) monoclo-
nal antibody and C20 (Santa Cruz Biotechnology) polyclonal antibody; anti-HA
antibody (12CA5, Roche Molecular Biochemicals) and anti-RIP monoclonal
antibody (Transduction Laboratory); anti-FAK phosphotyrosine Y397 antibody
(Biosourse International, Inc); and monoclonal anti--actin and anti-GST anti-
body (Sigma), anti-Xpress antibody and anti-Myc antibody (Invitrogen), and
anti-GFP antibody (Clontech).
Transfection. Cells were plated at a density of 2  106 cells per 100-mm
culture plate or 2  105 cells per well in six-well plates and allowed to attach for
24 h and then were transfected by using Lipofectamine (Invitrogen) for BT-474
and BT-20 cells and Effectene (QIAGEN) for HEK293 cells according to the
manufacturer’s instructions.
Immunoprecipitation and Western blotting. For cell lysate preparation, 1%
NP-40 lysis buffer was used (20 mM Tris-HCl [pH 8.0], 137 mM NaCl, 1%
Nonidet P-40, 10% glycerol, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluo-
ride, 10 g of aprotinin/ml, 20 g of leupeptin/ml). The protein concentration of
lysates was determined by using the bicinchoninic acid protein assay kit (Pierce,
Rockford, Ill.). For immunoprecipitation, lysates (500 g of total protein) were
precleared with protein A/G-agarose beads (Oncogene Research Products Inc.)
at 4°C for 1 h and then incubated with 5 l of antibody for 2 h followed by
overnight incubation with protein A/G-agarose beads at 4°C. Precipitates were
washed three times in lysis buffer, and beads were resuspended in sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample loading
buffer, boiled for 5 min, and resolved by SDS-PAGE. Proteins were transferred
to polyvinylidene difluoride membrane, probed with appropriate antibody, and
detected by chemiluminescence (KPL, Gaithersburg, Md.).
In vitro binding. GST fusion proteins were produced and purified as previ-
ously described (43). For in vitro binding assay, cell lysates were precleared with
GST protein (5 g), and the cleared supernatants (500 g) were incubated for
1 h at 4°C with 1, 5, or 10 g of GST fusion protein immobilized on glutathione-
agarose beads. Cell lysates were prepared from different cell lines or from 293
cells transfected with expression vectors encoding RIP, FAK, or its fragments.
The beads were washed twice with lysis buffer and twice with phosphate-buffered
saline (PBS). The bound proteins were analyzed by Western blotting.
Adenoviral infections. Adenovirus (Ad) FAK-CD (amino acids 693 to 1052 of
FAK fused to the HA epitope tag) was described previously (43). The Ad
carrying the lacZ gene was provided by J. Samulski (University of North Caro-
lina, Chapel Hill, N.C.). Cells were plated at a density of 2  106 cells per
100-mm culture plate or 2  105 cells per well in six-well plates, allowed to attach
for 24 h, and then infected with Ad FAK-CD or Ad LacZ for various times in
complete medium. We typically infected cells with 200 focus-forming units
(FFU)/cell, and expression was verified by Western blotting with an anti-HA
antibody that allowed us to estimate that infectivity and expression of Ad were
equal in all types of cells used.
Immunofluorescence staining. Cells were incubated in the presence or ab-
sence of staurosporine or Ad and stained with anti-FAK monoclonal antibody
4.47 as previously described (43).
siRNA synthesis and transfection. Small interfering RNAs (siRNAs) were
prepared according to the Silencer siRNA construction kit protocol (Ambion).
RIP siRNA H87 corresponded to the coding region 1129-1149 relative to the first
nucleotide of the start codon, and the RIP mRNA target sequence is 5-ACTC
CAAGACGAAGCCAAC-3. siRNA H121 corresponded to the coding region
1693-1713, and the RIP mRNA target sequence is 5-AGAAGAGCCAGCTG
CTAAG-3. siRNA H121Scr is a scrambled sequence of H121 siRNA. siRNA
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was synthesized accord-
ing to the Silencer kit protocol (Ambion). The transfection of siRNAs to target
the endogenous genes was carried out by using Oligofectamine (Invitrogen)
according to the manufacturer’s protocol.
PolyHEMA-coated tissue culture dishes. Tissue culture dishes were coated
with a film of poly(2-hydroxyethylmethacrylate) (polyHEMA; Sigma) as de-
scribed by Folkman and Moscona (6). Cells were trypsinized, resuspended, and
added to the plates coated with polyHEMA at a density of 2  106 cells per dish
in a serum-containing medium. Cells were maintained in suspension culture for
various times and assayed for cell survival by methods such as terminal de-
oxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL)
and methyl thiazole tetrazolium (MTT) assays.
Assays of cell viability. Detection of apoptosis was performed by TUNEL
assay and Hoechst 33342 staining. Cells were collected by centrifugation, fixed in
3.7% formaldehyde in 1 PBS for 10 min, washed twice with 1 PBS, and
stained with Hoechst 33342 or spread on the slide for TUNEL staining. TUNEL
assay was done with the ApopTag kit (Intergen, Purchase, N.Y.) according to the
manufacturer’s protocol. The percentage of apoptotic cells was calculated as the
ratio of apoptotic cells to the total number of cells counted with a fluorescence
microscope in several fields of three independent experiments. Simultaneous
staining and quantification of apoptotic cells with the Hoechst 33342 and
TUNEL methods produced very similar results. Cell survival was assayed by
measuring mitochondrial dehydrogenase activity, the conversion of soluble MTT
into insoluble formasan product, as described by Mosmant (29).
RESULTS AND DISCUSSION
Association between FAK and RIP in vivo and in vitro. To
determine whether there is a direct interaction between FAK
and RIP, we tested their binding in breast cancer cell lines.
Lysates were prepared from the BT-474 and BT-20 cell lines,
and coimmunoprecipitation experiments were performed with
antibody against FAK and RIP. We found a strong association
4.47 and C20 antibody and anti-RIP antibody. The expression of all constructs was confirmed with the corresponding antibody (data not shown).
(D) HEK293 cells were transiently cotransfected with pcDNA-Myc-RIP death domain along with pcDNA3-FAK, pGFP C1 vector, pGFP-FAK-
NT, or pGFP-FAK-CD. pCMV-CrmA was also included in the transfections. After 24 h, cell lysates were subjected to immunoprecipitation with
anti-Myc antibody. The immunopellets were analyzed by immunoblotting and probing with anti-FAK 4.47 and C20 antibody (data not shown) and
anti-GFP antibody. The expression of all constructs was confirmed by Western blot with the corresponding antibody (anti-Myc and anti-GFP
antibody). (E) Association of endogenous RIP with GST-FAK-NT fusion protein. GST protein and GST-fused FAK fragments (NT or FAT
domain) were bound to glutathione-Sepharose beads and used to pull RIP down from extracts of HEK293 cells, followed by SDS–10% PAGE.
The immunodetection first used anti-RIP antibody to detect pulled-down RIP, and then the blot was reprobed with anti-GST antibody. IP,
immunoprecipitation; IB, immunoblotting; Ab, probe without antibody; WB, Western blot.
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FIG. 2. Staurosporine causes dephosphorylation and degradation of FAK in breast carcinoma cell lines. A total of 2  105 cells from BT-20
or BT-474 cell culture were plated on six-well plates and were treated with staurosporine (200 nM) after 24 h. After 6 and 18 h of treatment, cells
were immunostained with anti-FAK 4.47 antibody, detached cells were counted, and cells were collected for TUNEL assay and Western blot
analysis. (A) Immunostaining of untreated cells and cells treated with staurosporine for 6 h (white arrowheads mark some focal adhesions).
(B) Western blot (WB) analysis of BT-20 and BT-474 lysates treated with staurosporine. Control cells were treated with dimethyl sulfoxide for 18 h.
(C) TUNEL assay data from one of three representative experiments.
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of FAK and RIP in both the BT-474 (Fig. 1A) and the BT-20
(data not shown) cell lines. To confirm the specificity of this
binding, we used an inducible system of FAK expression (Tet-
FAK cells) in FAK-null mouse embryonic fibroblasts, where
FAK expression is under the control of a tetracycline repressor
(31). Between 12 and 24 h after tetracycline withdrawal, cells
expressed high levels of FAK (Fig. 1B). Immunoprecipitation
of FAK from Tet-FAK cells demonstrated the association of
FAK and RIP, with the level of coimmunoprecipitation pro-
portional to the amount of FAK protein expression upon the
withdrawal of tetracycline from the medium. Taken together,
these results show that FAK and RIP bind together in both
breast cancer cell lines and mouse embryonic fibroblasts.
To define the RIP-binding domain in FAK as well as the
FAK-binding domain in RIP, we coexpressed different RIP
and FAK plasmids in HEK293 cells. Full-length RIP bound to
full-length FAK in HEK293 cells, and this binding appeared to
occur at the amino terminus of FAK, since antibody against the
C terminus of FAK (C20) did not reveal the FAK-CD protein
in immunoprecipitates (Fig. 1C). When we expressed the death
domain of RIP with different FAK constructs, RIP again
bound both to full-length FAK and to the amino terminus of
FAK (GFP-FAK-NT; Fig. 1D). To confirm this binding in
vitro, we used GST-FAK fusion proteins to test their ability to
bind to endogenous RIP in HEK293 cells. As shown in Fig. 1E,
RIP bound only to the amino terminus of FAK (GST-FAK-
NT), and did not bind to the focal adhesion targeting sequence
in the C terminus of FAK (GST-FAT) or to control GST.
From these experiments, we conclude that RIP binds to the
amino terminus of FAK through the death domain both in vivo
and in vitro.
Staurosporine-induced apoptosis causes RIP-dependent de-
phosphorylation and degradation of FAK. Next, we sought to
determine the biological significance of the FAK-RIP interac-
tion. First, we tested staurosporine, a bacterial alkaloid with
broad inhibitory activities against a variety of serine/threonine
kinases (34) and several tyrosine kinases (10, 30, 36). It also
induces apoptosis in a variety of transformed cell lines and has
been associated with FAK-mediated apoptosis in endothelial
cells (22). In breast cancer cells, we showed that staurosporine
caused a displacement of FAK from focal adhesions (Fig. 2A)
and led to rapid dephosphorylation and slower degradation of
FAK (Fig. 2B). We also found a decrease in the amount of RIP
protein associated with FAK in BT-474 cells 2 to 3 h after
treatment with staurosporine (data not shown), consistent with
disruption of the interaction of FAK and RIP.
In parallel with the degradation of FAK, we observed an
attenuation of RIP expression, resembling the proteosomal
degradation of RIP, that has been described during the dis-
ruption of the RIP-Hsp90 complex with geldanamycin (25).
Staurosporine induced different rates of apoptosis in these two
cell lines (Fig. 2C), and intriguingly, the apoptotic rate was
higher for the BT-474 cells that expressed significantly more
RIP than that for the BT-20 cells (Fig. 2B). Based on densi-
tometry analysis (data not shown), we estimated that BT-474
cells express 60% more RIP, suggesting that RIP may be pro-
viding proapoptotic signals in these breast cancer cells.
To specifically address this question, we tested staurosporine
on embryonic fibroblasts derived from normal and RIP/
mice (4). Staurosporine induced a higher rate of apoptosis in
the RIP/ cells than in the RIP/ cells (Fig. 3A). Further-
more, staurosporine caused a dose-dependent dephosphoryla-
tion and degradation of FAK in the RIP/ cells that was only
minimal in the RIP/ cells (Fig. 3B). The time course analysis
of staurosporine treated RIP/ and RIP/ mouse fibroblasts
by immunostaining and Western blot analysis showed that af-
ter 6 h of treatment, there were no focal adhesions in the rare,
attached RIP/ cells, while there were many attached RIP/
cells with visible focal adhesion structures (data not shown). In
FIG. 3. Staurosporine causes dephosphorylation and degradation
of FAK, which depends on the presence of RIP. A total of 2  105 cells
from RIP/ or RIP/ cell culture were plated on six-well plates and
were treated with staurosporine after 24 h. After 18 h of treatment,
detached cells were counted, and cells were collected for TUNEL
assay and Western blot analysis. (A) TUNEL assay data from one of
three representative experiments. (B) Western blot (WB) analysis of
RIP/ and RIP/ lysates treated with staurosporine.
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addition, RIP/ cells were resistant to FAK dephosphoryla-
tion and degradation, while FAK in RIP/ cells was rapidly
dephosphorylated and degraded (data not shown). These re-
sults show that the presence of RIP enhanced the rate of
staurosporine-induced apoptosis and the level of FAK dephos-
phorylation and degradation, suggesting that RIP provides
proapoptotic signals in these cells as well.
RIP is involved in transducing the proapoptotic signals ini-
tiated by the disruption of FAK signaling. To further define
the relationship between RIP and FAK, we studied apoptosis
that was induced by specific attenuation of FAK. We used our
model system in which the transduction of an adenoviral
FAK-CD construct into cells causes tyrosine dephosphoryla-
tion of FAK and displacement of FAK from the focal adhe-
sions. In breast cancer cell lines, this subsequently led to de-
tachment and apoptotic cell death, while in normal mammary
epithelial cells, the displacement of FAK appeared to have no
deleterious effect on the cells (43). Then, we applied this model
to test the effect of FAK attenuation on the RIP/ and
RIP/ fibroblasts. As shown in Fig. 4A, treatment of RIP/
cells with Ad FAK-CD did not lead to the displacement of
FAK from focal adhesions, while RIP/ cells showed dis-
placement of FAK beginning 6 h after treatment. In addition,
RIP/ cells did not detach from their substratum and had a
very low level of apoptosis (Fig. 4B). Furthermore, RIP/
cells had no significant changes in their level of FAK tyrosine
phosphorylation and did not have significant degradation of
FAK (Fig. 4C). In contrast, the RIP/ cells detached from
their substratum and underwent apoptosis (Fig. 4B) with cor-
responding changes in tyrosine phosphorylation and a result-
ant degradation of FAK (Fig. 4C). From these data, we con-
clude that the presence of FAK in the focal adhesions provides
antiapoptotic signals to the cells, and once FAK has been
displaced from focal adhesions, proapoptotic signals from RIP
promote apoptosis and degradation of FAK.
RIP is involved in transducing the detachment-induced ap-
optotic signals. Different groups have shown that FAK con-
trols adhesion-dependent cell survival in normal epithelial and
endothelial cells (9, 12, 16, 19). Results from previous studies
suggest that in breast tumor cells, FAK has two separate func-
tions, one promoting the adhesive interactions between tumor
cells and their extracellular matrix and the other acting as a
survival signal that is independent of cellular adhesion (43).
Thus, we compared the viability of RIP/ and RIP/ cells in
the absence of matrix attachment. Cells were maintained on
polyHEMA-coated tissue culture plates that create anchorage-
independent conditions. Both RIP/ and RIP/ cells re-
mained viable for at least 72 h, as determined by mitochondrial
dehydrogenase activity using the MTT assay (data not shown).
However, the viability of the suspended RIP/ cells was lower
than the viability of attached cells, with an average of 17% of
the cells undergoing apoptosis after 72 h in anchorage-inde-
pendent conditions (Fig. 5A) compared to 2% for the RIP/
cells (Fig. 5A). This result suggests that RIP may be involved
in transducing proapoptotic signals in anoikis. To examine
whether protection from anoikis required FAK, we attenuated
FAK with Ad FAK-CD. When RIP/ cells grown in suspen-
sion were transduced with Ad FAK-CD, their rate of apoptosis
was not different from RIP/ cells transduced with Ad LacZ
(Fig. 5B). In contrast, RIP/ cells had a much higher level of
apoptosis and became apoptotic much faster than RIP/ cells
when FAK signaling was disrupted (Fig. 5B). Thus, RIP/
cells were still sensitive to FAK attenuation under anchorage-
independent conditions. Taken together, these results demon-
strate that RIP provides proapoptotic signals in fibroblasts
grown in the absence of adhesion and that FAK plays an
additional role as an adhesion-independent survival signal not
only in transformed cells but also in normal fibroblasts.
Downregulation of RIP with siRNA in breast cancer cells
leads to higher resistance to apoptosis caused by the disrup-
tion of FAK signaling. While these results have provided evi-
dence of a proapoptotic role for RIP, we returned to our breast
cancer cell model to determine whether the downregulation of
RIP expression in BT-474 breast cancer cells could rescue
these cells from apoptosis induced by FAK attenuation. To
downregulate RIP expression, we synthesized two pairs of si-
lencing siRNAs corresponding to human RIP (H87 and H121),
which caused a moderate decrease in RIP expression in the
BT-474 cells (Fig. 6A). After 48 h of siRNA transfection, cells
were treated with either staurosporine (Fig. 6B and C) or
FAK-CD (Fig. 6D and E). In the cells treated with staurospor-
ine, a decrease in RIP expression by both RIP siRNAs pro-
tected FAK from rapid dephosphorylation during the first hour
of treatment, while control siRNAs (H121Scr and GAPDH)
had no effect. Longer treatment with staurosporine caused
apoptosis, the level of which was lower in the cells treated with
RIP siRNA (Fig. 6C). In the cells where FAK was specifically
downregulated by FAK-CD, the reduction of RIP expression
by siRNA also preserved a higher level of FAK phosphoryla-
tion even after a long exposure to FAK-CD. In contrast, FAK
was dephosphorylated in untreated control cells (Fig. 6D).
Furthermore, the rate of apoptosis (Fig. 6E) decreased from
42% in control cells to 22 and 15% in the H87 and H121
siRNA-treated cells, respectively. These results suggest that
increased levels of FAK expression, accompanied by de-
creased levels of RIP expression, enhance the survival sig-
nals in breast cancer cells and make them more resistant to
apoptotic stimuli.
These results provide a possible mechanistic explanation for
the prosurvival function of FAK in human breast cancer. FAK
binds to RIP in both normal and transformed cells, and the
disruption of the balance between these two kinases in a cell
may result in amplification of pro- or antiapoptotic stimuli.
This result is consistent with other reports, where it has been
FIG. 4. RIP is involved in transducing the proapoptotic signals initiated by the disruption of FAK signaling. A total of 2  105 cells from RIP/
or RIP/ cell culture were plated on six-well plates and were infected with Ad LacZ or Ad FAK-CD (200 FFU/cell) after 24 h. After 6 and 18 h
of treatment, cells were immunostained with anti-FAK 4.47 antibody (A) (white arrowheads mark some focal adhesions), detached cells were
counted, and cells were collected for TUNEL assay and Western blot analysis. (B) Detachment and apoptosis data from one of four representative
experiments. (C) Western blot (WB) analysis of RIP/ and RIP/ lysates treated with Ad LacZ or Ad FAK-CD.













































FIG. 5. RIP is involved in transducing the detachment-induced proapoptotic signals. (A) A total of 2  106 RIP/ and RIP/ cells were
plated on tissue culture dishes coated with polyHEMA and were grown in complete medium for 24 to 72 h. TUNEL assay and Hoechst staining
were performed at the indicated time points. TUNEL assay data from one of three representative experiments are shown. (B) A total of 2  105
RIP/ and RIP/ cells were plated on tissue culture dishes coated with polyHEMA and were grown in complete medium for 24 to 72 h and then
transduced with either Ad LacZ control or Ad FAK-CD for 24 h. TUNEL assay and Hoechst staining were performed at the indicated time points.
TUNEL assay data from one of three representative experiments are shown.
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FIG. 6. Downregulation of RIP with siRNA leads to higher resistance to apoptosis caused by the attenuation of FAK. A total of 2  105 BT474
cells were plated on six-well plates and were transfected with siRNA (25 nM) after 24 h. (A) Forty-eight hours after transfection, cells were
collected and analyzed by Western blotting (WB). Controls: scrambled RIP H121 siRNA (H121Scr), GAPDH siRNA, and cells treated with
transfection reagent alone (lanes 3, 4, and 5, respectively). (B and C) After 48 h of transfection, cells were treated with 200 nM staurosporine and
collected 1 h later to analyze tyrosine phosphorylation of FAK (B) or collected 18 h later for TUNEL assay (C). (D and E) After 48 h of
transfection, adenoviral infection was performed and Ad LacZ and Ad FAK-CD were added to the cell cultures (200 FFU/cell). After 18 h of
infection, detached cells were counted, and cells were collected for TUNEL assay and Western blot analysis. (D) Western blot analysis with
anti-FAK phosphotyrosine Y397 antibody. (E) TUNEL assay data from one of three representative experiments.
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shown that RIP may provide proapoptotic signals in some
cases or antiapoptotic signals in others (14, 23, 28). Thus,
our model suggests that the upregulation of FAK expression
in cancer cells shifts the FAK-RIP balance towards resis-
tance to apoptosis and promotes survival of the cells. Fi-
nally, these results may provide the link between FAK and
the death receptor for the phenomenon of anoikis. Tumor
cells have been postulated to be resistant to anoikis to allow
them to survive during the processes of invasion and metas-
tasis that require anchorage-independent survival (15). As
tumor cells become detached and proceed with invasion and
metastasis, our model predicts that FAK would bind to RIP
and provide survival signals to these cells. Thus, this pro-
posed mechanism suggests that targeting the FAK-RIP as-
sociation might provide a novel approach for cancer thera-
peutics.
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